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Abstract
Background: Randomized clinical trials (RCTs) have demonstrated the efficacy of implan-
table cardioverter-defibrillators (ICDs) in reducing sudden cardiac death (SCD) in specific
patient populations. However, patients ≥ 65 years were under-represented in these trials and
the overall benefit of ICDs may be diminished in older patients due to competing risks for
death. We evaluate the published data on ICD efficacy at reducing all-cause mortality in
patients ≥ 65 years and in patients ≥ 75 years.
Methods: We searched MEDLINE to identify RCTs and observational studies of ICDs that
provided age-based outcome data for primary prevention of SCD. The primary endpoint was
mortality evaluated by a meta-analysis of the RCTs using a random-effects model. Secondary
endpoints included operative mortality, long-term complications and quality of life.
Results: The enrollment of patients ≥ 65 years in RCTs was limited (range: 33% in DEFI-
NITE to 56% in MUSTT). Combining data from four RCTs (n = 3,562) revealed that
primary prevention ICD therapy is efficacious in reducing all-cause mortality in patients ≥ 65 ye-
ars (HR 0.66; 95% CI 0.50–0.87; test of heterogeneity: X2 = 5.26; p = 0.15). For patients
≥ 75 years, combining data from four RCTs (n = 579) revealed that primary prevention ICD
therapy remains efficacious in reducing all-cause mortality (HR 0.73; 95% CI 0.51–0.974;
p = 0.03). There appears to be no difference in ICD-related, operative, in-hospital, or long-
-term complications among older patients compared to younger patients, although it remains
unclear if older patients have a better quality of life with an ICD than younger patients.
Conclusions: Although the overall evidence regarding ICD efficacy in patients ≥ 65 years is
limited and divergent, and the evidence available for patients ≥ 75 years is even more sparse,
our meta-analysis suggests that primary prevention ICDs may be beneficial in older patients.
Our findings need to be validated by future studies, particularly ones examining ICD compli-
cations and quality of life. (Cardiol J 2011; 18, 5: 503–514)
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Introduction
In the United States, sudden cardiac death
(SCD) accounts for more than 350,000 deaths an-
nually, disproportionately affecting those aged
≥ 65 years [1]. Currently, implantable cardioverter-
-defibrillators (ICDs) are the most effective treat-
ment for patients at high risk of SCD. As a result,
their use rose 20–30% annually throughout the
1990s [2]. However, individual randomized con-
trolled trials (RCTs) of ICDs enrolled relatively few
patients aged 65 years or older, and even fewer of
these patients were aged 75 years or older [3–10].
Thus, the optimal use of ICDs in the older popula-
tion remains uncertain.
Clinically, patients aged ≥ 65 years are distinct-
ly different from their younger cohorts. Advanced
age is often accompanied by greater susceptibility
to complications and adverse effects of therapies,
as well as more co-morbidities and multi-system
diseases that increase the risk of non-SCD. Conse-
quently, the risks of ICD implantation may be higher
and the potential benefits of ICD therapy may be
reduced in this patient population [11]. Given the
limited evidence and the potential for disparate
risks and benefits in this population, we conducted
a systematic review of the published literature to
evaluate the body of evidence addressing the use
of ICDs in patients aged ≥ 65 years and performed
the first formal meta-analysis of the primary pre-
vention trials in the growing subpopulation of pa-
tients aged ≥ 75 years.
Methods
Data sources and study selection
We conducted a systematic search of MED-
LINE, Cochrane Controlled Trials Register,
clinicaltrials.gov, and fda.gov using the terms
“defibrillator” or “clinical trial” (Fig. 1). Limiting
our search to peer-reviewed studies performed in
humans and published in English since 1 January,
1990, we identified 1,540 potentially relevant cita-
tions, of which 1,306 were excluded at the abstract
screening stage. Studies of cardiac resynchroniza-
tion therapy, studies that included ICD therapy in
both treatment and control arms, and studies lack-
ing estimates of ICD effect based on age were ex-
cluded (n = 1,306). Studies enrolling < 100 pa-
tients or lacking age subgroup analyses were also
excluded (n = 195), leaving 39 studies for review.
Of these, secondary prevention RCTs and substud-
ies or meta-analyses of secondary prevention
RCTs were excluded (n = 8). A review of the refe-
rences cited in the remaining 31 studies did not
identify any additional studies that met inclusion
criteria.
Non-randomized prospective or retrospective
case series investigating the effectiveness of ICDs
based on age (n = 6) were found and included in
the literature review, along with publications of
primary prevention RCTs (n = 9) and their substu-
dies (n = 10). However, only RCTs were included
in the meta-analysis. Of the nine primary preven-
tion RCTs, only five were selected for the meta-
analysis. Of the four RCTs that were excluded, CAT
and AMIOVIRT were excluded due to lack of esti-
mates of ICD effect based on age, and DINAMIT
and CABG-PATCH were excluded a priori due to
their enrollment of markedly different patient popu-
lations than the RCTs that were included. Due to
this significant heterogeneity, including DINAMIT
and CABG-PATCH in the meta-analysis would not
be valid. Additionally, COMPANION was not includ-
ed in our meta-analysis because this trial was de-
signed to evaluate cardiac resynchronization the-
rapy, and not ICD therapy.
Data extraction and synthesis
Abstracts of identified studies were reviewed
independently by two investigators (MHK, GDS).
We abstracted data from each article on study de-
sign, treatment, patient and clinical characteristics,
outcomes, subgroup findings, ICD complications,
and quality of life (QoL). Discrepancies between
reviewers were resolved through discussion. For
the meta-analysis, the primary outcome of interest
was all-cause mortality in patients ≥ 65 years old.
Although not every study included in the meta-ana-
lysis provided the subgroup analysis for patients
≥ 65 years or for patients ≥ 75 years, we obtained
these data for each RCT from the trials’ principal
investigators. Likewise, for the overall review, the
primary endpoint was mortality. Secondary end-
points included operative mortality, long-term com-
plications and QoL.
Statistical methods
To be included in the meta-analysis, all studies
had to be randomized clinical trials with an approp-
riate control analyzed by the intention-to-treat princi-
ple. Using an empirical Bayes random-effects estima-
tor, we combined trial-level data on older patients from
the major RCTs of primary prevention ICDs, which
represent populations for which ICDs are recom-
mended [12]. When no heterogeneity is present, this
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estimator reduces to a fixed effects estimator. The
estimates were computed using Comprehensive
Meta-Analysis SoftwareTM (BIOSTAT, Englewood,
NJ, USA). Statistical heterogeneity was measured
using the c2 test. Statistical tests were two-tailed, and
statistical significance was declared at p < 0.05. We
did not combine data on older patients from the ma-
jor RCTs of secondary prevention ICDs as this has
been done previously [13].
Results
ICDs for primary prevention of SCD
in patients aged 65 years and older
Table 1 presents data on the mean age of pa-
tients enrolled in the nine RCTs of primary preven-
tion ICDs [3–9, 14, 15].  The number of patients
≥ 65 years ranged from 55% in the Multicenter Un-
sustained Tachycardia Trial (MUSTT) to 34% in the
Figure 1. QUOROM flowchart; CRT — cardiac resynchronization therapy; ICD — implantable cardioverter-defibrilla-
tor; RCT — randomized clinical trials.
506
Cardiology Journal 2011, Vol. 18, No. 5
www.cardiologyjournal.org
Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation (DEFINITE) trial [16].
Defibrillator in Acute Myocardial Infarction Trial
(DINAMIT) data was not available. Five RCTs pro-
vided data on primary prevention ICDs in patients
≥ 65 years (Table 2) [1, 6, 8, 9, 17, 18]. Of these
trials, MUSTT enrolled the highest percentage of
patients > 65 years (55.97%) and the oldest patient
population (mean age 66 years) [7]. A MUSTT sub-
study explored the effect of age on ICD benefit by
examining 243 patients aged ≥ 70 years and showed
that the benefit from ICD therapy was similar in
older and younger patients [17].
The Multicenter Automatic Defibrillator Im-
plantation Trial-II (MADIT-II) randomized patients
with a prior myocardial infarction and left ventricu-
lar ejection fraction (LVEF) £ 30% to ICD therapy
or conventional medical therapy. Of this population,
1,028 patients were < 75 years of age, and 204 pa-
tients were ≥ 75 years of age. Hazard ratios (HR)
for the three predefined age subsets were 0.46 for
age < 60 years; 0.77 for age 60–69 years; and 0.65
for age ≥ 70 years [6]. Subsequently, two substud-
ies from MADIT-II addressed the effect of age on
ICD efficacy (Table 2) [1, 18]. Patients aged ≥ 75 ye-
ars in MADIT-II had a HR of 0.56 compared with
conventional therapy (95% CI 0.29–1.08; p = 0.08)
[18]. The second substudy re-examined the pre-
specified age subgroups (< 65, 65–74, and ≥ 75 ye-
ars of age) to assess ICD benefit with respect to age
[1]. In patients aged ≥ 75 years, there was a 68%
reduction in the risk of SCD with ICD therapy and
Table 1. Randomized controlled trials of implantable cardioverter-defibrillator (ICD) therapy in primary
prevention of sudden cardiac death.
Trial (year) Treatment Patients Mean age Patients Hazard ratio for effect
group  (years)  ≥ 65 y/o (%)  of ICD therapy on
all-cause mortality (95% CI)
MADIT-I (1996) [5] Total 196 63±9* 53.5 0.46 (0.26–0.82)
ICD 95 62±9 53.5
Control 101 64±9 53.5
CABG-PATCH (1997) [4] Total 900 64±9* 49.89 1.07 (0.81–1.42)
ICD 446 64±9 50.0
Control 454 63±9 50.0
MUSTT (1999) [7] Total 704 66.5*† 55.97 0.45 (0.32–0.63)
ICD 161 65.4 (8.52)‡ 56.9
Control 543 64.9 (9.65)‡ 54.1
CAT (2002) [14] Total 104 52±11 NR 0.83 (0.45–1.52)
ICD 50 52±12 NR
Control 54 52±10 NR
MADIT-II (2002) [6] Total 1,232 64±10* 48.0 0.69 (0.51–0.93)
ICD 742 64±10 44.2
Control 490 65±10 51.4
AMIOVIRT (2003) [15] Total 103 NR NR NR
ICD 51 58±11 NR
Control 52 60±12 NR
DINAMIT (2004) [3] Total 674 62±11* NR 1.08 (0.76–1.55, p = 0.66)
ICD 332 61.5±10.9 NR
Control 342 62.1±10.6 NR
DEFINITE (2004) [8] Total 458 58.3 34.28 0.65 (0.40–1.06, p = 0.08)
ICD 229 58.4 35.4
Control 229 58.1 33.2
SCD-HeFT (2005) [9] Total 2,521 60*† 34.49 0.77 (0.62–0.96, p = 0.007)§
ICD 829 60.1† 35.5
Control (amiodarone) 845 60.4† 33.5
Control (placebo) 847 59.7†
NR — not reported; *values not reported in original trial publications, but obtained from reference [45]; †median; ‡mean (standard deviation);
§97.5% confidence interval (CI)
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this finding was similar in patients aged 65–74 ye-
ars. The greatest benefit of ICD therapy for all-
cause mortality was seen in the group aged 65–74 ye-
ars, who experienced a 37% reduction (p = 0.03),
while younger patients experienced a 21% reduc-
tion (p = 0.35), and older patients a 30% reduction
(p = 0.20). However, these results also need to be
interpreted cautiously given the known limitations
of subgroup analyses [19].
The DEFINITE trial comprised exclusively
patients with non-ischemic cardiomyopathy and
thus enrolled a younger patient population, with
a mean age of 58 years. DEFINITE suggested that
patients aged ≥ 65 years derived similar benefit from
ICD therapy as did their younger counterparts [8].
An age-related subgroup analysis of the Sud-
den Cardiac Death in Heart Failure Trial (SCD-
-HeFT) showed greater benefit in ICD recipients
< 65 years [9]. The largest of the primary preven-
tion trials, SCD-HeFT enrolled 2,521 patients with
NYHA class II–III congestive heart failure and an
LVEF ≥ 35% and randomized patients to placebo,
amiodarone, or a single-lead ICD [9]. Compared to
placebo, ICD therapy resulted in a 23% reduction
in risk of death. For the group aged ≥ 65 years, ICD
implantation compared to placebo carried a favor-
able HR of 0.86, but the 97.5% CI crossed unity
(0.62–1.18), reflecting the smaller sample size of the
older age group (n = 578) compared to their younger
counterparts (n = 1,098; HR 0.68; 97.5% CI 0.50–0.93).
Combining data from MADIT-I, MADIT-II,
DEFINITE, and SCD-HeFT, we found ICDs to be
efficacious in reducing all-cause mortality in pa-
tients ≥ 65 years (HR 0.66; 95% CI 0.50–0.87; test
Table 2. Effect of age on implantable cardioverter-defibrillator (ICD) efficacy in substudies and subgroup
analyses from randomized clinical trials of ICD therapy for the primary prevention of sudden cardiac
death (SCD).
Author (year) Parent trial Age Patients Hazard ratio for effect
subgroups  of ICD therapy on all-cause
(years)  mortality (95% CI)
Moss (1996) [5] MADIT-I None 196 For patients ≥ 65: 0.38 (0.17–0.86)*
Bigger (1997) [4] CABG-PATCH None 900 No significant difference in HR for ICD
 group compared to control therapy
 in subgroup analysis stratified by
 age. However, for patients ≥ 65:
1.216 (0.858–1.724)*
Moss (2002) [6] MADIT-II < 60 370 0.46 (0.23–0.93)†
60–69 426 0.77 (0.47–1.25)†
≥ 70 436 0.65 (0.42–0.98)†
Peterson (2003) [17]§ MUSTT < 70 461 0.52 (0.33–0.77)†
≥ 70 243 0.43 (0.27–0.80)†
Greenberg (2004) [48] MADIT-II None 1,232 0.33 (0.20–0.53, p < 0.0001).
No significant difference in
reduction of SCD by ICD in
subgroup analysis stratified by age
Kadish (2004) [8] DEFINITE < 65 301 0.70 (0.35–1.40)†
≥ 65 157 0.63 (0.32–1.23)†
Hohnloser (2004) [3] DINAMIT < 60 275 HR < 1.0, 95% CI crosses 1.0‡
≥ 60 399 For patients ≥ 65: 1.23 (0.82–1.84)*
Bardy (2005) [9] SCD-HeFT < 65 1,098 0.68 (0.50–0.93)
≥ 65 578 0.86 (0.62–1.18)
Huang (2007) [18] MADIT-II < 75 1,028 0.63 (0.45–0.88, p = 0.01)
≥ 75 204 0.56 (0.29–1.08, p = 0.08)§
Goldenberg (2007) [1] MADIT-II < 65 574 0.79 (0.48–1.29)
65–74 455 0.63 (0.41–0.95)
≥ 75 204 0.70 (0.41–1.20)§
NA — not applicable; *hazard ratios (HR) and confidence intervals (CI) not published, but obtained from personal communication with trial investiga-
tors; †HR and CI not reported in original trial publications, but obtained from reference [45]; ‡exact point estimates have not been published; §these
published point estimates for the 204 patients in MADIT-II ≥ 75 years of age are different because each was derived using a different statistical model
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of heterogeneity: X2 = 5.26; p = 0.15). When we
included the MUSTT trial, ICD therapy was still
efficacious in reducing all-cause mortality (HR 0.60;
95% CI 0.45–0.78); however, there was a trend to-
ward significant heterogeneity among the trials
(X2 = 8.01; p = 0.09) (Figs. 2A, B). This increased
heterogeneity may reflect the fact that, unlike the
other trials included, ICD therapy was not randomi-
zed in MUSTT.
ICDs for primary prevention of SCD
in patients aged 75 years and older
The number of patients ≥ 75 years ranged from
17% in MADIT-II to 9% in MADIT-I, DEFINITE,
and SCD-HeFT alike (Table 3) [5, 6, 8, 9]. Four
RCTs provided data on primary prevention ICDs in
patients ≥ 75 years (Table 3) [6–9]. There were no
deaths among the 18 patients aged ≥ 75 years ran-
domized to the ICD treatment arm of MADIT-I, and
as such a HR was not calculable [5]. Combining data
from MUSTT, MADIT-II, DEFINITE, and SCD-
-HeFT, we found that ICDs remained efficacious in
reducing all-cause mortality in patients ≥ 75 years
(HR 0.73; 95% CI 0.51–0.974; p = 0.03) (Fig. 3).
Non-randomized studies of ICDs
in older patients
Numerous non-randomized studies have at-
tempted to examine the efficacy of ICD implanta-
tion in older patients (Table 4) [20–24]. One study
Figure 2. Hazard ratios for all-cause mortality in patients ≥ 65 years with MUSTT (A) and without MUSTT (B).
Table 3. Randomized controlled trials of implantable cardioverter-defibrillator (ICD) therapy in primary
prevention of sudden cardiac death.
Trial (year) Patients Patients Patients Hazard ratio for effect
≥ 75 y/o (n)  ≥ 75 y/o (%)  of ICD therapy on all-cause
mortality (95% CI)
MADIT-I (1996) [5] 196 18 9.18 No deaths in ICD treatment arm
MUSTT (1999) [7] 704 96 13.6 1.00 (0.58–1.75)
MADIT-II (2002) [6] 1,232 204 16.6 0.71 (0.42–1.19)
DEFINITE (2004) [8] 458 43 9.4 0.29 (0.09–0.97)
SCD-HeFT (2005) [9] 2,521 236 9.4 0.65 (0.39–1.05)
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examined patients who received ICDs for primary
prevention indications. Others included both se-
condary and primary prevention indications. A few
studies included patients who had received an ICD
for either secondary or primary prevention indica-
tions [20–24]. Two of these studies found ICDs to
be of similar effectiveness in older and younger pa-
tients [20, 22], and three studies found that younger
patients derived more benefit than older patients [21,
23, 24]. These studies were limited by small sample
sizes, non-randomized design, and lack of appropri-
ate adjustment for different sources of bias.
Only one study was limited to patients with
a primary prevention indication for an ICD [25].
This study prospectively enrolled 965 patients, with
or without an ICD, and with either ischemic or non-
-ischemic cardiomyopathy. Using a landmark analy-
sis and multivariable Cox proportional hazards mo-
dels that included propensity scores for ICD im-
plantation, this study showed that ICD use was
associated with lower all-cause mortality, even
among older patients and those with co-morbid con-
ditions [25].
In-hospital complications in patients
aged 65 and older
Of all patients receiving an ICD, about 30%
experience one or more complications post-implan-
tation, 10% of which are directly related to the im-
plantation procedure [26]. The inherent risks of ICD
implantation must therefore be considered when
evaluating their potential use in older patients [27].
Although sparse, current evidence suggests that
ICD operative mortality may be independent of age.
In one case series of consecutive patients referred
to a single institution for ICD implantation, mor-
tality was similar in patients aged ≥ 70 years vs
< 70 years [28].
Complications related to ICD implantation in-
clude atrial or ventricular lead dislodgement or frac-
ture, device migration or malfunction, pneumotho-
rax, damage to arteries and nerves, air embolism,
vein thrombosis, cardiac perforation and resultant
pericardial effusion with or without tamponade,
pocket hematoma, pocket or systemic infection, and
arrhythmias related to lead manipulation [29].
A study of Medicare Provider Analysis and Review
(MedPAR) files from fiscal year 2003 analyzed
31,000 Medicare beneficiaries receiving ICDs as an
isolated procedure in 2002–2003. It found that the
rate of one or more in-hospital complications relat-
ed to ICD implantation was 10.8% [30]. In this
study, the age distribution was similar among pa-
tients who experienced complications compared to
those who did not. Another retrospective database
analysis of prospectively collected data from a sin-
gle center stratified patients into two groups: pa-
tients aged 70–79 years and ≥ 80 years [20]. Ex-
cept for age, the two groups were similar demo-
graphically, and had similar actuarial survival rates
and complication rates (p = 0.16). A third retrospec-
tive case series of 450 patients who underwent ICD
implantation at a single center found that periope-
rative mortality by age group was not significantly
different among age groups [11].
More recently, a study of Medicare beneficia-
ries who received an ICD between 2002 and 2005
examined patient and implanting physician factors
associated with the outcomes of ICD implantation
[31]. The mean age of the 8,581 patients who had
an ICD implanted during the study period was
75 years. Age was not found to be an independent
risk factor for increased complications [31].
Long-term ICD complications
in patients aged 65 and older
Little is known about the long-term complica-
tions of ICD therapy in the general population, and
as such, even less can be extrapolated to older pa-
tients. Based on data from 500 consecutive patients
Figure 3. Hazard ratios for all-cause mortality in patients ≥ 75 years.
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enrolled in the Marburg Defibrillator Database,
rates of inappropriate shocks over a 48 month period
were similar for patients aged ≥ 75 years compared
to patients aged < 75 years (3% vs 13%; p = 0.29)
[23]. Rates of generator-related complications and
total mortality were higher among the older sub-
group compared to the younger subgroup (33% vs
20%; p = 0.01). However, the number of older pa-
tients was very small, making the true long-term
complication rate uncertain.
In the aforementioned study on patient and
implanting physician factors associated with out-
comes of ICD therapy in Medicare beneficiaries, the
one-year mortality rate declined from 16.4% in 2002
to 13.2% in 2005 (p < 0.001) [31]. Older age was
found to be independently associated with an in-
creased risk of one-year mortality. Additional risk
factors for increased mortality included history of
myocardial infarction, congestive heart failure,
chronic lung disease, dementia, diabetes, metastatic
cancer, peripheral vascular disease, renal disease,
and admission from the emergency room, many of
which are more often found in older patients with
significant co-morbid illnesses.
Effect of age on quality of life
in ICD patients
Equally important to understanding the mor-
bidity and mortality risks associated with ICD im-
plantation are the QoL implications of ICDs in old-
er patients. Three of the large RCTs have systema-
tically examined the impact of ICD therapy on QoL
— MADIT-II, CABG-PATCH, and most recently,
SCD-HeFT [32–36]. However, short follow-up and
methodological issues have limited the value of
these substudies. Furthermore, it remains unclear
how ICDs affect QoL in patients who receive pri-
mary prevention ICDs [36]. The largest QoL study
in ICD recipients for primary prevention of SCD
was performed in the SCD-HeFT population; how-
ever, the effect of age on QoL was not examined.
The only study that examined the relationship
between age and QoL in the setting of a RCT was
a MADIT-II substudy that included 1,089 patients
and measured Health Utility Index-3 scores at
three, 12, 24, and 36 months following enrollment
[35]. Mean patient age in this substudy was approxi-
mately 65 years. Patients in the control group main-
tained a steady health-related quality of life
(HRQOL), while ICD patients showed a gradually
diminishing HRQOL. The declining average
HRQOL in the control group was only due to mor-
tality, but in the ICD group it was due to both mor-
tality and decreasing HRQOL values for survivors.
The difference in quality adjusted life years (QALY)
between the two groups was not statistically sig-
nificant. Within this study, key subgroup analyses
were performed and for patients ≥ 65 years there
was no significant decrease in QALYs while alive.
The relationship between age and QoL has
been examined in several non-randomized studies
[18, 35, 37, 38]. These studies were limited by small
sample size, non-randomized study design, and lack
of adjustment for potential confounders. Nonethe-
less, in general, these studies showed that although
older patients with ICDs had decreased physical
functioning, more co-morbid illness, and worse
symptoms that negatively impact QoL, younger
patients with ICDs tended to experience increased
psychological distress, anxiety, and depression,
which negatively impact QoL.
Discussion
With the aging of the US population, expand-
ing indications for ICD implantation, and growing
evidence favoring device-based therapy over anti-
arrhythmic drugs, data on the utilization and effica-
cy of ICDs in older patients is becoming increas-
ingly important.
Despite the growing body of evidence from
numerous large RCTs demonstrating that ICDs
improve survival rates in various subsets of pa-
tients, the mean age of the patients enrolled in the
RCTs of primary prevention ICDs was < 65 years
and no RCT has prospectively focused on evaluat-
ing the outcomes and efficacy of these devices in
patients aged ≥ 65 years, much less in those pa-
tients aged ≥ 75 years. In fact, some trials have pur-
posely excluded patients over 80 years of age [3, 4,
39]. Still, conclusions about the impact of ICDs for
the primary prevention of SCD in older patients are
often extrapolated from such studies performed in
these younger patient subgroups with mean ages
much less than 65 years. In light of the established
guidelines, an RCT specifically addressing ICD
therapy in the older population is unlikely to be
performed. Our meta-analysis and systematic litera-
ture review highlights the considerable under-rep-
resentation of older patients in the available RCTs.
Additionally, the validity of the non-randomized, ret-
rospective studies is unclear, since they did not ad-
just for inherent selection biases and their study po-
pulations consisted of patients who had already been
referred for, or had already received, ICD therapy.
Given the limited number of older patients
enrolled in the primary prevention RCTs of ICD
therapy, we combined data from four major RCTs
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of primary prevention ICDs (MADIT-I, MADIT-II,
DEFINITE, and SCD-HeFT). We chose these tri-
als to minimize heterogeneity because all of them
randomized patients to ICD vs a control arm, and
the patients enrolled were similar. The results of
our meta-analysis are concordant with a recent quali-
tative overview that concluded that the relative
benefit of ICD therapy is somewhat higher in older
than in younger patients in MADIT-II, MUSTT, and
DEFINITE; somewhat lower in older than in young-
er patients in SCD-HeFT; and equivocal, but tend-
ing toward harm, in the older group compared to
the younger group in DINAMIT [40]. A few stud-
ies have examined the effect of age at implantation
on outcomes after ICD implantation. Most trials
only provide follow-up data ranging from 3–6 years,
so longer-term outcomes remain largely unknown
[36]. Likewise, very little is known about the physi-
cal, emotional, and social adjustments associated
with ICD implantation and the impact of age on
these factors. As such, concerns are frequently
raised about the effect of advanced age on the out-
comes, cost–effectiveness, and QoL of such patients
who receive ICDs. Based on our review of the lite-
rature, there appears to be no difference in opera-
tive, in-hospital, or long-term complications among
older patients compared to younger patients [11, 18,
20, 23, 28].
One of the goals of our paper was to highlight
the fact that there is extremely little QoL data on
the use of ICDs in older patients — a subpopula-
tion in which QoL is often a critical factor in clinical
decision making. At this time, it remains unclear if
older patients actually have a better QoL with an
ICD than younger patients [35, 37, 41–44].
Two qualitative reviews have addressed the
use of ICDs in older patients [1, 45]. Each review
describes RCTs of ICD therapy for both secondary
and primary prevention and includes descriptions
of a few non-randomized cohort studies of ICD thera-
py in older patients. In contrast, our systematic lite-
rature review provides the first and only formal
meta-analysis of data on patients ≥ 65 years and
≥ 75 years from the major RCTs on primary pre-
vention ICDs. Additionally, our review examines in
more detail both perioperative and long-term com-
plications in older patients, and considers the effect
of age on QoL in patients with ICDs.
In contrast to our findings, a recently published
meta-analysis by Santangeli et al. [46] examined the
effectiveness of ICDs for the primary prevention of
SCD in older patients using data from MADIT-II,
DEFINITE, and SCD-HeFT and found only a mini-
mal and statistically non-significant survival bene-
fit in older patients (HR 0.81; 95% CI 0.62–1.05;
p = 0.11). However, the analysis by Santangeli et
al. [46] defined older patients as those ≥ 60 years
of age, combined data from one study for patients
≥ 60 years old with data from other studies for pa-
tients ≥ 65 years old, and did not include data from
the MADIT-I and MUSTT trials of primary preven-
tion, citing the unavailability of this data.
While RCTs will provide the strongest data on
ICDs in patients ≥ 65 years, data on ICD benefit in
older patients can be gleaned from registries of
patients in the general population. One such regis-
try is the American College of Cardiology-National
Cardiovascular Data Registry (ACC-NCDR)-opera-
ted National ICD Registry. Since Medicare pa-
tients account for 70% of all patients entered into
the National ICD Registry, this registry provides
a unique opportunity to address key questions re-
levant to clinical practice that remain unanswered
by the numerous, large RCTs [47]. Long-term out-
comes data will be evaluated by combining the ICD
Registry with the Medicare Claims Database and
potentially with the National Death Index and as
such, the National ICD Registry will more accurate-
ly reflect the costs and outcomes of ICDs implanted
in older patients seen in general clinical practice
compared to the highly selected, younger patient
populations with fewer co-morbidities typically en-
rolled in RCTs [38]. Although this data will be use-
ful, one limitation of this type of data source is the
lack of a control group, because everyone enrolled
in the registry will have received an ICD.
Our study has some limitations. As with any
literature search of databases like PubMed, publi-
cation bias cannot be excluded and our inclusion of
only published, peer-reviewed studies contributes
to selection bias. Similarly, our decision to meta-
analyze only RCTs may not reflect patients in gene-
ral clinical practice because trial populations are
often highly-selected patient subgroups. Finally, the
lack of patient-level data precluded more detailed
analyses such as examination of the extremely small
subgroup of octogenarians who received primary
prevention ICDs.
Conclusions
In contrast to a previously published age-spe-
cific meta-analysis demonstrating a lack of ICD ef-
ficacy for the secondary prevention of SCD in pa-
tients ≥ 75 years, our meta-analysis of ICD use for
primary prevention of SCD suggests that ICDs may
be beneficial for older patients, including those pa-
tients ≥ 75 years.
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Given that the current data supporting the ef-
ficacy of ICD therapy in older patients is sparse and
inconclusive, implanting an ICD in an older patient
should be a decision made between the patient and
the physician, which takes into account each indi-
vidual’s overall health status, co-morbidities, physi-
cal and mental functioning, and personal preferenc-
es. The use of ICDs in older patients should not be
withheld based on age alone.
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